Earnings results for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc. is expected* to report earnings on 11/09/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.09. The reported EPS for the same quarter last year was $0.13.
Catalyst Pharmaceuticals last released its earnings results on August 10th, 2020. The biopharmaceutical company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.08 by $0.01. The firm had revenue of $29.61 million for the quarter, compared to analyst estimates of $28.97 million. Catalyst Pharmaceuticals has generated $0.30 earnings per share over the last year and currently has a price-to-earnings ratio of 8.1. Catalyst Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Monday, November 9th, 2020.
Analyst Opinion on Catalyst Pharmaceuticals (NASDAQ:CPRX)
5 Wall Street analysts have issued ratings and price targets for Catalyst Pharmaceuticals in the last 12 months. Their average twelve-month price target is $8.67, predicting that the stock has a possible upside of 175.13%. The high price target for CPRX is $12.00 and the low price target for CPRX is $6.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $8.67, Catalyst Pharmaceuticals has a forecasted upside of 175.1% from its current price of $3.15. Catalyst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals does not currently pay a dividend. Catalyst Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Catalyst Pharmaceuticals (NASDAQ:CPRX)
In the past three months, Catalyst Pharmaceuticals insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $65,480.00 in company stock and sold $0.00 in company stock. Only 10.70% of the stock of Catalyst Pharmaceuticals is held by insiders. 62.56% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Catalyst Pharmaceuticals (NASDAQ:CPRX
Earnings for Catalyst Pharmaceuticals are expected to grow by 2.44% in the coming year, from $0.41 to $0.42 per share. The P/E ratio of Catalyst Pharmaceuticals is 8.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 19.85. The P/E ratio of Catalyst Pharmaceuticals is 8.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.08. Catalyst Pharmaceuticals has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here